Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
about
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Tofacitinib with conventional ...... 3 randomized controlled trial.
@en
Tofacitinib with conventional ...... 3 randomized controlled trial.
@nl
type
label
Tofacitinib with conventional ...... 3 randomized controlled trial.
@en
Tofacitinib with conventional ...... 3 randomized controlled trial.
@nl
prefLabel
Tofacitinib with conventional ...... 3 randomized controlled trial.
@en
Tofacitinib with conventional ...... 3 randomized controlled trial.
@nl
P2093
P2860
P356
P1476
Tofacitinib with conventional ...... 3 randomized controlled trial.
@en
P2093
Houheng Su
Jianhua Xu
Kenneth Kwok
Xiangpei Li
Zhanguo Li
P2860
P304
P356
10.1111/1756-185X.13244
P577
2018-01-04T00:00:00Z